Actively Recruiting

Phase Not Applicable
Age: 18Years - 100Years
All Genders
NCT05344651

Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium

Led by Oogziekenhuis Rotterdam · Updated on 2022-12-13

160

Participants Needed

1

Research Sites

188 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Rationale: The Baerveldt glaucoma drainage device (GDD) successfully reduces intraocular pressure but also involves a risk of corneal endothelial deterioration. Supposedly, the tip of a GDD tube with a thinner diameter, such as the Paul implant, will remain at a larger distance from the cornea and, thereby, cause less damage. Objective: To determine whether the Paul tube induces less damage to the corneal endothelium than the Baerveldt GDD. Study design: Randomized clinical trial. Study population: Phakic patients scheduled for surgical GDD implantation. Intervention: Either a Baerveldt or a Paul GDD implant. Main study parameters/endpoints: Endothelial cell density and tube position at 24 months. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The Paul GDD may have a less harmful effect on corneal endothelium. Otherwise, both GDDs will probably have a similar risk/benefit profile. The risks of study-related assessments are negligible, burden is low, extra time is about 5 x 1.5 h (total 7.5 h) in two years.

CONDITIONS

Official Title

Comparing the Baerveldt and Paul Glaucoma Drainage Devices and Their Effects on the Corneal Endothelium

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age over 18 years
  • Provided informed consent
  • Caucasian ethnicity as self-reported or based on parents' origin
  • Diagnosed with primary open-angle glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma
Not Eligible

You will not qualify if you...

  • History of intraocular surgery such as vitrectomy, cataract surgery, or cyclodestructive procedures
  • History of ocular comorbidities including active uveitis or proliferative diabetic retinopathy
  • Presence of pseudophakia (artificial lens)
  • Functionally monocular patients
  • Need for glaucoma surgery combined with other eye surgeries like cataract surgery, keratoplasty, or retinal surgery
  • Narrow anterior chamber angle
  • Best corrected visual acuity less than 0.1
  • Severe blepharitis

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Oogziekenhuis Rotterdam

Rotterdam, Netherlands, 3011BH

Actively Recruiting

Loading map...

Research Team

R

Rene J Wubbels

CONTACT

S

Susan Marinissen

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here